This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Al-Sulaiman, A. M.
Right arrow Articles by Klapper, P. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Sulaiman, A. M.
Right arrow Articles by Klapper, P. E.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, June 2009, p. 931-934, Vol. 16, No. 6
1071-412X/09/$08.00+0     doi:10.1128/CVI.00036-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Comparative Performance of a Novel Herpes Simplex Virus Type 2-Specific Enzyme-Linked Immunosorbent Assay Using a Targeted Chain Oligopeptide, Peptide 55{triangledown}

A. M. Al-Sulaiman,1* P. J. Vallely,1 and P. E. Klapper2

Virology, Genomic Epidemiology Research Group, School of Translational Medicine, University of Manchester, Manchester, United Kingdom,1 Clinical Virology, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom2

Received 14 November 2008/ Returned for modification 27 February 2009/ Accepted 9 April 2009

Herpes simplex virus (HSV) glycoprotein G (gG2) has been used as the basis of many serological assays for the detection of HSV type 2 (HSV-2)-specific antibodies. In the present study, an enzyme-linked immunosorbent assay (ELISA), the Pathozyme Viro HSV-2 immunoglobulin G (IgG) ELISA (Omega Diagnostics, Alva, United Kingdom), based on an immunodominant epitope of gG2 presented in a branched-chain format (peptide 55), was compared with two commercially available gG2-specific assays, the Bioelisa HSV-2 IgG assay (Biokit, S.A., Barcelona, Spain) and the HerpesSelect HSV-2 IgG assay (Focus Diagnostics, Cypress, CA). A panel of 218 well-characterized serum samples was tested. Thirty-one samples were determined to be HSV-2 IgG antibody positive and 164 samples were determined to be negative with all three kits. The levels of concordance between the tests were 95.9% between the Omega and HerpeSelect assays, 90.8% between the Omega and Bioelisa assays, and 94.5% between the HerpeSelect and Bioelisa assays. Twenty-three samples gave discordant results. Western blot results showed that of these, the results for 77% were correctly identified by the Omega assay, the results for 68% were correctly identified by the HerpeSelect assay, and the results for 13.6% were correctly identified by the Bioelisa assay. Although there was a high level of agreement between the results obtained by the three assays and no false-positive results were detected by any of the three kits, confirmation of the results for samples with discordant results by Western blotting suggested that the peptide 55-based Omega assay is the most sensitive and specific assay among the assays evaluated.

* Corresponding author. Mailing address: University Virology, 3rd Floor Clinical Sciences Building, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, United Kingdom. Phone: 441612768841. Fax: 441612768840. E-mail: Alsulaiman{at}postgrad.manchester.ac.uk

{triangledown} Published ahead of print on 15 April 2009.

Clinical and Vaccine Immunology, June 2009, p. 931-934, Vol. 16, No. 6
1071-412X/09/$08.00+0     doi:10.1128/CVI.00036-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»